INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGXPRNewsWire • Thursday
Argenx Slumps On Mixed Third Quarter, Surprise Vyvgart Testing PlansInvestors Business Daily • 10/22/26
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026GlobeNewsWire • 10/15/26
ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS LawBusiness Wire • 10/12/26
argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX)PRNewsWire • 10/08/26
argenx shares drop after trial of Vyvgart in Sjögren's disease is haltedProactive Investors • 10/08/26
Former Highflier Argenx Plummets On A Surprise Setback In Sjogren'sInvestors Business Daily • 10/08/26
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionBenzinga • 10/08/26
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac DiseaseGlobeNewsWire • 10/08/26
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's DiseaseGlobeNewsWire • 10/08/26
10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?The Motley Fool • 10/05/26
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability ConsortiumBusiness Wire • 09/29/26
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular PipelineGlobeNewsWire • 09/29/26